Rafael Holdings, Inc. Class B (RFL)

Over the past six months, Rafael Holdings' stock price has declined by approximately 29.06%. As of January 7, 2026, the share price was $1.30, a 32.99% decrease from January 8, 2025. The stock's 52-week high was $2.44, and its low was $1.28. Key events include reporting a net loss of $30.5 million in fiscal 2025, the passing of its Lead Independent Director and appointment of a new board member, presentation of preliminary data from a Phase 3 study, abstracts accepted for presentations at a congress, and Howard S. Jonas reassuming the CEO role.

The provided information does not contain specific details regarding demand seasonality for Rafael Holdings, Inc.'s products and services. Demand for its primary product candidate, Trappsol® Cyclo™, would likely be driven by clinical trial progress, regulatory approvals, and the prevalence of Niemann-Pick Disease Type C1 (NPC1), rather than typical seasonal consumer patterns. The company's revenue generation is primarily from capital allocation and the potential value creation from its clinical-stage pharmaceutical pipeline, rather than commercial sales.

Rafael Holdings, Inc. is a clinical-stage biotechnology company with interests in real estate and infusion technology. Its core focus is developing novel therapeutics for difficult-to-treat diseases through its subsidiary, Cyclo Therapeutics, LLC. The company is listed on the NYSE and is advancing its lead drug candidate, Trappsol® Cyclo™, which is in Phase 3 clinical trials for Niemann-Pick Disease Type C1 (NPC1). Rafael Holdings also holds interests in other clinical and early-stage pharmaceutical companies and is involved in developing Promitil for targeted drug delivery in advanced cancers, as well as surgical and procedural devices. Beyond healthcare, Rafael Holdings maintains a real estate segment and an Infusion Technology segment.

Rafael Holdings, Inc. conducts its operations in the United States and Israel and is headquartered in Newark, New Jersey, United States.

Information specifically detailing Rafael Holdings, Inc.'s brand reputation is not explicitly available. However, the company's strategic shifts and clinical trial outcomes are significant events that would inherently influence its reputation. The failure of Devimistat in pivotal trials in 2021 and the subsequent termination of a planned merger in 2022 led to a strategic reassessment. The merger with Cyclo Therapeutics in March 2025 and a $25.0 million rights offering in June 2025 demonstrate a commitment to its new direction, which would likely shape perceptions of the company's stability and future prospects.

Ownership of Rafael Holdings, Inc. is a mix of institutional, insider, and retail investors. Howard S. Jonas, the Executive Chairman and CEO, is the largest individual shareholder, owning 29.02% of all shares and 50.4% of the voting power. Major institutional shareholders include Vanguard Group Inc., BlackRock, Inc., Ieq Capital, Llc., Geode Capital Management, Llc., and Dimensional Fund Advisors Lp. Other significant shareholders include i9 PLUS, L.L.C. and William Conkling. As of Q4 2025, 92 institutions held shares of Rafael Holdings, Inc. Insider sentiment for RFL is positive.